Table 1.
Baseline Characteristics
| Candesartan group (n = 12) | Placebo group (n = 12) | P | |
|---|---|---|---|
| Age, y | 41 ± 15 | 45 ± 13 | 0.56 |
| Male sex, n (%) | 5 (42) | 6 (50) | NS |
| Cardiac symptoms, n (%) | 8 (67) | 7 (58) | NS |
| Family history | |||
| HCM, n (%) | 7 (58) | 8 (67) | NS |
| SCD, n (%) | 3 (25) | 3 (25) | NS |
| Myofilament genotype | |||
| ß-MHC, n (%) | 5 (42) | 4 (33) | |
| cMYBPC, n (%) | 3 (25) | 3 (25) | |
| cTnT, n (%) | 0 | 0 | NS |
| cTnI, n (%) | 2 (17) | 1 (8) | |
| Myofilament genotype-negative, n (%) | 2 (17) | 2 (17) | |
| Medication | |||
| ß-blockers, n (%) | 4 (33) | 4 (33) | |
| Verapamil, n (%) | 4 (33) | 4 (33) | NS |
| ß-blockers and verapamil, n (%) | 1 (8) | 1 (8) |
ß-MHC = ß-myosin heavy chain, cMYBPC = cardiac myosin binding protein C, cTnT = cardiac troponin T, cTnI = cardiac troponin I, HCM = hypertrophic cardiomyopathy, SCD = sudden cardiac death.